Takeda Pharmaceutical's (TAK) "Hold (C+)" Rating Reaffirmed at Weiss Ratings

Key Points

• Takeda Pharmaceutical had its "hold (C+)" rating reaffirmed by Weiss Ratings, amidst mixed analyst sentiments concerning the stock's performance.
• The stock recently rose 0.5% to $13.79, with a market capitalization of approximately $43.86 billion.
• While one analyst rates Takeda as a Buy and another as a Sell, the company's average rating remains a "Hold," reflecting ongoing uncertainty in its market position.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report)'s stock had its "hold (c+)" rating reaffirmed by stock analysts at Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports.

Separately, Zacks Research downgraded Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research note on Thursday, August 21st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical presently has an average rating of "Hold".

Takeda Pharmaceutical Stock Up 0.5%

NYSE TAK traded up $0.07 on Tuesday, reaching $13.79. The stock had a trading volume of 2,326,422 shares, compared to its average volume of 2,600,979. The business has a 50 day moving average price of $14.85 and a 200 day moving average price of $14.78. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. Takeda Pharmaceutical has a 1 year low of $12.80 and a 1 year high of $15.69. The company has a market capitalization of $43.86 billion, a price-to-earnings ratio of 45.95 and a beta of 0.21.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, analysts forecast that Takeda Pharmaceutical will post 1.64 EPS for the current fiscal year.

Institutional Trading of Takeda Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC raised its holdings in shares of Takeda Pharmaceutical by 3.3% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 22,088 shares of the company's stock worth $341,000 after buying an additional 715 shares in the last quarter. Sage Rhino Capital LLC boosted its position in shares of Takeda Pharmaceutical by 7.9% in the 2nd quarter. Sage Rhino Capital LLC now owns 12,604 shares of the company's stock worth $195,000 after purchasing an additional 919 shares during the last quarter. Jackson Thornton Wealth Management LLC boosted its position in shares of Takeda Pharmaceutical by 7.8% in the 2nd quarter. Jackson Thornton Wealth Management LLC now owns 12,779 shares of the company's stock worth $192,000 after purchasing an additional 920 shares during the last quarter. Intelligence Driven Advisers LLC boosted its position in shares of Takeda Pharmaceutical by 7.2% in the 2nd quarter. Intelligence Driven Advisers LLC now owns 14,535 shares of the company's stock worth $225,000 after purchasing an additional 977 shares during the last quarter. Finally, Ieq Capital LLC boosted its position in shares of Takeda Pharmaceutical by 4.6% in the 1st quarter. Ieq Capital LLC now owns 22,222 shares of the company's stock worth $330,000 after purchasing an additional 981 shares during the last quarter. Institutional investors own 9.17% of the company's stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.